Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.

Details

Language :

English

ISSN :

00916749

Volume :

138

Issue :

6

Database :

Supplemental Index

Journal :

Journal of Allergy & Clinical Immunology

Publication Type :

Academic Journal

Accession number :

119773632

Full Text :

https://doi.org/10.1016/j.jaci.2016.07.015